Bio-Rad Laboratories, Inc. Class B (BIO.B) AI Stock Analysis

Bio-Rad Laboratories, Inc. Class B

(NYSE:BIO.B)

Select Model

Rating:50Neutral

Price Target:$373.00▲(0.85% Upside)

Action:initiatedcoverage

Date:10/23/26

The overall score reflects a company in transition with significant near-term headwinds. The primary positive is a very strong balance sheet that provides financial security. However, this is outweighed by weak technical momentum, a high valuation, and an earnings outlook that points to flat-to-declining revenues. The restructuring plan offers a path to improved profitability, but benefits will not materialize until 2027.

Positive Factors

Balance Sheet StrengthConservative leverage and a large equity cushion give Bio-Rad financial resilience while preserving flexibility for investment, acquisitions, restructuring, and shareholder returns. Lower total debt versus 2025 further reduces balance-sheet pressure as the company manages uneven operating performance.

Negative Factors

Weak Revenue OutlookThe full-year outlook indicates that Bio-Rad is still operating in a weak demand environment, particularly in Life Science. Near-flat to declining revenue limits operating leverage, makes growth investment harder to absorb, and delays a clearer recovery in the company's earnings base.

Bio-Rad Laboratories, Inc. Class B (BIO.B) vs. SPDR S&P 500 ETF (SPY)

Market Cap: $10.46B
Dividend Yield: ―
Average Volume (3M): 157
Price to Earnings (P/E): 44.7
Beta (1Y): 1.01
Revenue Growth: 1.37%
EPS Growth: -29.25%
Country: US
Employees: 7,450
Sector: Healthcare
Sector Strength: 51
Industry: Medical - Devices

Bio-Rad Laboratories, Inc. Class B Business Overview & Revenue Model

Company Description

Bio-Rad Laboratories, Inc. creates, manufactures, and markets products essential for life science research and clinical diagnostics. Its operations span globally, covering territories such as the United States, Europe, Asia, Canada, and Latin America...

Bio-Rad Laboratories, Inc. Class B Financial Statement Overview

Summary

Financial performance is mixed. A fortress balance sheet with low debt (0.17 D/E) provides stability, but this is offset by a highly volatile income statement with declining revenues and historically weak profitability. Cash flow is positive but inconsistent, with a significant TTM decline in free cash flow.

Income Statement

35Negative

Balance Sheet

72Positive

Cash Flow

55Neutral

Financial statement breakdown
Breakdown	TTM	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021
Income Statement
Total Revenue	2.59B	2.58B	2.57B	2.67B	2.80B	2.92B
Gross Profit	1.34B	1.34B	1.38B	1.43B	1.57B	1.64B
EBITDA	514.70M	1.21B	-2.14B	-654.80M	-4.53B	5.59B
Net Income	222.40M	759.90M	-1.84B	-637.32M	-3.63B	4.25B
Balance Sheet
Total Assets	10.25B	10.58B	9.36B	12.30B	13.50B	17.80B
Cash, Cash Equivalents and Short-Term Investments	1.62B	1.54B	1.66B	1.61B	1.79B	869.92M
Total Debt	1.20B	1.53B	1.37B	1.41B	1.39B	223.38M
Total Liabilities	3.08B	3.12B	2.79B	3.56B	3.89B	4.11B
Stockholders Equity	7.17B	7.45B	6.57B	8.74B	9.62B	13.69B
Cash Flow
Free Cash Flow	353.10M	374.60M	266.20M	218.26M	80.29M	535.72M
Operating Cash Flow	492.60M	532.20M	455.20M	374.94M	194.45M	669.46M
Investing Cash Flow	-237.10M	-189.70M	-160.20M	20.21M	-1.21B	-797.38M
Financing Cash Flow	-121.10M	-283.20M	-218.80M	-425.65M	973.58M	-55.43M

Bio-Rad Laboratories, Inc. Class B Technical Analysis

Technical Analysis SentimentPositive

Last Price369.85

Price Trends

50DMA382.76Negative

100DMA353.72Positive

200DMA318.72Positive

Market Momentum

MACD1.34Negative

RSI53.50Neutral

STOCH69.25Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For BIO.B, the sentiment is Positive. The current price of 369.85 is below the 20-day moving average (MA) of 373.83, below the 50-day MA of 382.76, and above the 200-day MA of 318.72, indicating a neutral trend. The MACD of 1.34 indicates Negative momentum. The RSI at 53.50 is Neutral, neither overbought nor oversold. The STOCH value of 69.25 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for BIO.B.

Bio-Rad Laboratories, Inc. Class B Peers Comparison

Overall Rating

UnderperformOutperform

Sector (51)

Financial Indicators

BIO.B against its peers
Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	51Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
BIO.B	50Neutral	$10.00B	44.68	3.15%	―	1.37%	-29.25%

* Healthcare Sector Average

Performance Comparison

BIO.B and its peers over the selected period
Show on chart	Ticker	Company Name	Price	Change	% Change
	BIO.B	Bio-Rad Laboratories, Inc. Class B	382.23	71.13	22.86%

Glossary

BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Date of analysis: Oct 23, 2026

Bio-Rad Laboratories, Inc. Class B AI Stock Analysis